Lonza, Teva to Form Biosimilars JV

Lonza and Teva Pharmaceutical Industries (Petah Tikva, Israel) say they have agreed to establish a joint venture to develop, manufacture and market a portfolio of biosimilars. The joint venture is expected to commence activities during the first quarter of 2009, subject to receipt of regulatory approvals. Financial details of the deal were not disclosed. The two companies will cooperate to develop, manufacture and market a number of affordable, efficacious and safe generic equivalents of a selected portfolio of biologic pharmaceuticals. “We had identified...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers